NCT04329728 2026-04-15
OPAL
AVM Biotechnology Inc
Phase 1/2 Recruiting
Clinical Trials
29 trialsNCT06651970 2026-04-15
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Phase 4 Recruiting
NCT00923507 2026-04-14
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT04728893 2026-04-13
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06564038 2026-04-13
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT07511426 2026-04-06
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
Phase 1 Recruiting
NCT06208735 2026-04-03
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
Phase 1 Recruiting
NCT05254743 2026-04-01
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT06542250 2026-03-27
TITANium
AstraZeneca
Phase 1/2 Recruiting
NCT07487428 2026-03-23
CLL-IMPACT
Technical University of Munich
Phase NA Recruiting
NCT06859424 2026-03-17
ACCELERATE
Center for International Blood and Marrow Transplant Research
Phase 2 Recruiting
NCT05442515 2026-03-12
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05557695 2026-03-10
EPIC
AstraZeneca
Recruiting
NCT07422337 2026-02-25
BOOSTER
Arkansas Children's Hospital Research Institute
Recruiting
NCT05589896 2026-02-24
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Phase 1/2 Recruiting
NCT06357754 2026-01-22
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Bristol-Myers Squibb
Recruiting
NCT06662227 2026-01-20
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT05362773 2026-01-13
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT06708897 2025-12-05
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Lomond Therapeutics Holdings, Inc.
Phase 1 Recruiting
NCT05010564 2025-11-13
TRICAR-ALL
Baylor College of Medicine
Phase 1 Recruiting
NCT03050190 2025-09-08
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT03125577 2025-09-08
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT06812715 2025-08-06
PIPOZA
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT06834529 2025-02-19
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Recruiting
NCT06821880 2025-02-12
PRO-SID
Medical University Innsbruck
Recruiting
NCT06355739 2024-04-09
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT05082519 2023-10-26
IDEAL2
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Recruiting
NCT03899337 2023-01-09
STELLAR
University of Birmingham
Phase 2 Recruiting
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting